A federal jury has ordered Wyeth Pharmaceuticals and Upjohn to pay more than $27 million to Donna Scroggin of Little Rock, AR. Scroggin sued the companies in 2004 after developing breast cancer following hormone replacement therapy with drugs manufactured by the companies. The jury said that Wyeth inadequately warned her that its drugs Premarin and Prempro carried an increased risk of breast cancer.

Wyeth has had its share of lawsuits over the years. Another woman from Little Rock, Helene Rush, lost her case last year against the company. An Ohio woman was initially awarded $3 million in a case in Pennsylvania but a judge later overturned it. In Reno last year, jurors awarded $134 million to three Nevada women who sued over the hormone therapy. However, a judge cut that amount to $58 million. This is the largest award to date against the Wyeth company. It currently faces 5,300 similar lawsuits and plans on appealing the Scroggin ruling.

Both of the company’s drugs in question, Premarin, an estrogen replacement and Prempro, a combination of estrogen and progestin, still remain on the market and are approved by the U.S. Food and Drug Administration and continue to be prescribed to hundreds of thousands of women every year to relieve symptoms of menopause.